82508-37-0

Usage

Uses

Used in Pharmaceutical Industry:
Deacetylpseudolaric acid A is used as an anti-cancer agent for its potent cytotoxic and anti-tumor activities. It is particularly effective in inducing apoptosis, inhibiting cell proliferation, and disrupting the cell cycle in various cancer cell lines, making it a valuable component in the development of novel cancer treatments.
Used in Anti-inflammatory Applications:
Deacetylpseudolaric acid A is used as an anti-inflammatory agent due to its ability to reduce inflammation and suppress the immune system, which can be beneficial in the treatment of various inflammatory diseases.
Used in Immunosuppressive Therapy:
Deacetylpseudolaric acid A is used as an immunosuppressive agent to modulate the immune response, which can be advantageous in managing autoimmune conditions and in the context of organ transplantation to prevent rejection.

Upstream product

• 82508-32-5 pseudolaric acid A 
• 915708-13-3 2-(2,2-diethyl-4-methyl-[1,3]dioxolan-4-yl)-5-(4-methoxy-benzyloxymethyl)-8-methyl-11-oxa-tricyclo[5.3.1.0^1,5]undecan-8-ol 
• 915708-12-2 2-(2,2-diethyl-4-methyl-[1,3]dioxolan-4-yl)-5-(4-methoxy-benzyloxymethyl)-11-oxa-tricyclo[5.3.1.0^1,5]undecan-8-one 
• 915708-14-4 8-chloro-2-(2,2-diethyl-4-methyl-[1,3]dioxolan-4-yl)-5-(4-methoxy-benzyloxymethyl)-8-methyl-11-oxa-tricyclo[5.3.1.0^1,5]undecane 
• 915708-15-5 3-(2,2-diethyl-4-methyl-[1,3]dioxolan-4-yl)-8a-(4-methoxy-benzyloxymethyl)-6-methyl-2,3,4,5,8,8a-hexahydro-1H-azulen-3a-ol 
• 915708-16-6 3-(2,2-diethyl-4-methyl-[1,3]dioxolan-4-yl)-8a-hydroxymethyl-6-methyl-2,3,4,5,8,8a-hexahydro-1H-azulen-3a-ol 
• 915708-21-3 1-(2,2-diethyl-4-methyl-[1,3]dioxolan-4-yl)-8a-hydroxy-6-methyl-2,3,4,7,8,8a-hexahydro-1H-azulene-3a-carbaldehyde 

Downstream Products

• 82508-32-5 pseudolaric acid A 

Relevant academic research and scientific papers

Discovery of pseudolaric acid A as a new Hsp90 inhibitor uncovers its potential anticancer mechanism

Pseudolaric acid A (PAA), one of the main bioactive ingredients in traditional medicine Pseudolarix cortex, exhibits remarkable anticancer activities. Yet its mechanism of action and molecular target have not been investigated and remain unclear. In this work, mechanistic study showed that PAA induced cell cycle arrest at G2/M phase and promoted cell death through caspase-8/caspase-3 pathway, demonstrating potent antiproliferation and anticancer activities. PAA was discovered to be a new Hsp90 inhibitor and multiple biophysical experiments confirmed that PAA directly bind to Hsp90. Active PAA-probe was designed, synthesized and biological evaluated. It was subsequently employed to verify the cellular interaction with Hsp90 in HeLa cells through photoaffinity labeling approach. Furthermore, NMR experiments showed that N-terminal domain of Hsp90 and essential groups in PAA are important for the protein-inhibitor recognition. Structure-activity relationship studies revealed the correlation between its Hsp90 inhibitory activity with anticancer activity. This work proposed a potential mechanism involved with the anticancer activity of PAA and will improve the appreciation of PAA as a potential cancer therapy candidate.

Total synthesis of pseudolaric acid A

(Chemical Equation Presented) The antiangiogenic and cytotoxic natural product pseudolaric acid A ((-)-1) has been obtained by a 26-step synthetic route. This enantioselective synthesis employed an intramolecular carbene cyclization cycloaddition cascade